References of "Beguin, Yves"
     in
Bookmark and Share    
Full Text
See detailLes anticorps monoclonaux en hématologie en 2009
Bonnet, Christophe ULg; Beguin, Yves ULg; De Prijck, Bernard ULg et al

in Revue Médicale de Liège (2009), 64

Directed against the CD20 antigen on B lymphocytes, rituximab (MabThera) is now incorporated in the first line therapy of symptomatic follicular as well as diffuse large B cell non-Hodgkin's lymphoma and ... [more ▼]

Directed against the CD20 antigen on B lymphocytes, rituximab (MabThera) is now incorporated in the first line therapy of symptomatic follicular as well as diffuse large B cell non-Hodgkin's lymphoma and offers superior response and survival rates. 90Y ibritumomab tiuxetan (Zevalin) combines the specificity of rituximab for the CD20 antigen and the therapeutic effect of β irradiation. Given in monotherapy, it constitutes an interesting alternative therapy for follicular lymphomas in second relapse. Alemtuzumab (MabCampath) recognizes the CD52 antigen and offers encouraging results in chronic lymphocytic leukemia resistant to classical chemotherapy. [less ▲]

Detailed reference viewed: 154 (14 ULg)
Full Text
See detailTraitements actuels du lymphome folliculaire
Bonnet, Christophe ULg; Beguin, Yves ULg; De Prijck, Bernard ULg et al

in Revue Médicale Suisse (2009), 5

After diffuse large B-cell lymphoma, follicular lymphoma is the most frequent non-Hodgkin's lymphoma. It remains incurable, except for localized diseases. Advanced disease has to be treated only in the ... [more ▼]

After diffuse large B-cell lymphoma, follicular lymphoma is the most frequent non-Hodgkin's lymphoma. It remains incurable, except for localized diseases. Advanced disease has to be treated only in the presence of clinical and/or biology aggressiveness. These patients should be treated by rituximab (Mab-Thera) associated to polychemotherapy comprising cyclophosphamide, vincristine and prednisone. After this therapy, the benefit of rituximab in maintenance has to be confirmed. Autologous stem cell transplantation is also an interesting option. The other therapeutic options comprise radio-immunotherapy with 90Y ibritumomab tiuxetan (Zevalin) and bortezomib (Velcade). [less ▲]

Detailed reference viewed: 410 (4 ULg)
Full Text
See detailEx vivo expansion of hematopoietic progenitor cells is associated with downregulation of alpha4 integrin- and CXCR4-mediated engraftment in NOD/SCID beta2-microglobulin-null mice
Foguenne, Jacques ULg; Di Stefano; Giet, Olivier ULg et al

in Haematologica (2009), 94

Several studies indicate that ex vivo cytokine-supported expansion induces defective hematopoietic stem cell engraftment. We investigated the role of alpha4 integrin, alpha5 integrin and CXCR4 in ... [more ▼]

Several studies indicate that ex vivo cytokine-supported expansion induces defective hematopoietic stem cell engraftment. We investigated the role of alpha4 integrin, alpha5 integrin and CXCR4 in engraftment of unmanipulated and cytokine-treated human cord blood CD34+ cells. [less ▲]

Detailed reference viewed: 37 (18 ULg)
Full Text
See detailKIR-ligand incompatibility in the Graft-versus-host direction improves outcome after umbilical cord blood transplantation for acute leukemia
Willemze, R.; Rodrigues, C. A.; Labopin, M. et al

in Leukemia : Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K (2009), 23

Detailed reference viewed: 24 (5 ULg)
Full Text
See detailUtilisation thérapeutique de l'érythropoïétine
Beguin, Yves ULg

in Revue du Praticien (La) (2009), 59

Detailed reference viewed: 35 (9 ULg)
Full Text
See detailWhat is the Role for Regulatory T-Cells after Nonmyeloablative conditioning
Humblet-Baron, S.; CASTERMANS, Emilie ULg; Vanbellighen, J.-F. et al

in Biology of Blood & Marrow Transplantation (2008, February), 14(2), 136-137

Detailed reference viewed: 10 (2 ULg)
Full Text
See detailEvidence for neo-generation of T cells by the thymus after non-myeloablative conditioning.
Castermans, Emilie ULg; Baron, Frédéric ULg; Willems, Evelyne ULg et al

in Haematologica (2008), 93(2), 240-7

BACKGROUND: Background and objective. We investigated immune recovery in 50 patients given either unmanipulated or CD8-depleted allogeneic peripheral blood stem cells after non-myeloablative conditioning ... [more ▼]

BACKGROUND: Background and objective. We investigated immune recovery in 50 patients given either unmanipulated or CD8-depleted allogeneic peripheral blood stem cells after non-myeloablative conditioning. DESIGN AND METHODS: Fifty patients were randomized to receive either CD8-depleted (n=22) or non-manipulated (n=28) peripheral blood stem cells. The median patients age was 57 (range 36-69) years. The conditioning regimen consisted of 2 Gy total body irradiation with or without added fludarabine. Twenty patients received grafts from related donors, 14 from 10/10 HLA-allele matched unrelated donors, and 16 from HLA-mismatched unrelated donors. Graft-versus-host disease pro-phylaxis consisted of mycophenolate mofetil and cyclosporine. Immune recovery during the first year after hematopoietic cell transplantation was assessed by flow cytometry phenotyping, analyses of the diversity of the TCRBV repertoire, and quantification of signal-joint T-cell receptor excision circles (sjTREC). RESULTS: CD8-depletion of the graft reduced the recovery of CD8(+) T-cell counts in the first 6 months following transplantation (p<0.0001) but had no significant impact on the restoration of other T-cell subsets. Both sjTREC concentration and CD3(+) T-cell counts increased significantly between day 100 and 365 (p=0.010 and p=0.0488, respectively) demonstrating neo-production of T cells by the thymus. Factors associated with high sjTREC concentration 1 year after transplantation included an HLA-matched unrelated donor (p=0.029), a high content of T cells in the graft (p=0.002), and the absence of chronic graft-versus-host disease (p<0.0001). CONCLUSIONS: Our data suggest that while immune recovery is mainly driven by peripheral expansion of the graft-contained mature T cells during the first months after non-myeloablative transplantation, T-cell neo-generation by the thymus plays an important role in long term immune reconstitution in transplanted patients. [less ▲]

Detailed reference viewed: 156 (85 ULg)
Full Text
See detailCord blood banking
Brand, A.; Rebulla, P.; Engelfriet, C. P. et al

in Vox Sanguinis (2008), 95

Detailed reference viewed: 80 (3 ULg)
Full Text
See detailPrediction of response to recombinant human erythropoietin in the anemia of cancer
Beguin, Yves ULg; Vanstraelen, Gaetan

in Nowrousian, M. R. (Ed.) Recombinant human erythropoietin (rhEPO) in clinical oncology (2nd Ed.) (2008)

Detailed reference viewed: 11 (1 ULg)
Full Text
See detailrhEPO in hematopoietic stem cell transplantation
Vanstraelen, Gaetan; Beguin, Yves ULg

in Nowrousian, M. R. (Ed.) Recombinant human erythropoietin (rhEPO) in clinical oncology (2nd Ed.) (2008)

Detailed reference viewed: 11 (3 ULg)
Full Text
See detailComment je traite...La leucémie myéloblastique aiguë (LMA) du sujet age en bon état général.
Lejeune, Marie ULg; Beguin, Yves ULg; De Prijck, Bernard ULg et al

in Revue Médicale de Liège (2008), 63(2), 59-63

This article describes the treatment of acute myeloid leukemia in older patients with good performance status, and then discusses briefly some future therapeutic perspectives.

Detailed reference viewed: 153 (6 ULg)
Full Text
See detailCord blood transplantation in a child with Pearson's disease.
Hoyoux, Claire; Dresse, Marie-Françoise ULg; Robinet, Sébastien ULg et al

in Pediatric Blood & Cancer (2008), 51(4), 566

Detailed reference viewed: 36 (4 ULg)
Full Text
See detailIron deficiency
Beguin, Yves ULg; Estatiev, R.

in Gasche, C. (Ed.) Anemia in inflammatory bowel disease (2008)

Detailed reference viewed: 8 (2 ULg)
Full Text
See detailErythropoiesis
Beguin, Yves ULg

in Gasche, C. (Ed.) Anemia in inflammatory bowel disease (2008)

Detailed reference viewed: 13 (5 ULg)
Full Text
See detailLe sang de cordon ombilical
Beguin, Yves ULg

in Revue du Praticien (La) (2008), 58

Detailed reference viewed: 22 (4 ULg)
Full Text
See detailThe hematopoiesis-supporting activity of mesenchymal stem cells increases with the number of passages
Briquet, Alexandra ULg; Beguin, Yves ULg; Gothot, André ULg

in Experimental Hematology (2007, September), 35(9, Suppl. 2), 125-125

Detailed reference viewed: 24 (11 ULg)
Full Text
See detailStudy of contribution of signalling pathways Notch, Wnt, Shh and BMP in mesenchymal stem cell prohaematopoietic activity
Briquet, Alexandra ULg; Dolhet, Marie; Demeuse, Jessica et al

in Acta Clinica Belgica (2007, August), 62(4), 256

Detailed reference viewed: 11 (1 ULg)
Full Text
See detailMature erythrocyte parameters as new markers of functional iron deficiency in haemodialysis: sensitivity and specificity
Bovy, Christophe ULg; Gothot, André ULg; Krzesinski, Jean-Marie ULg et al

in Nephrology Dialysis Transplantation (2007), 11

Background. The percentage of hypochromic red blood cells (RBCs) (%HYPO) has been demonstrated as the best predictor of response to iron loading in haemodialysis patients treated with recombinant human ... [more ▼]

Background. The percentage of hypochromic red blood cells (RBCs) (%HYPO) has been demonstrated as the best predictor of response to iron loading in haemodialysis patients treated with recombinant human erythropoietin (rHuEPO). However, we have previously shown that this parameter is positively influenced by erythropoietic activity since reticulocytes are considered hypochromic by cell counters. New cell counters are able to determine cell volume and haemoglobin (Hb) concentration separately on reticulocytes and mature erythrocytes. The aim of this study was to assess the sensitivity and specificity of mature erythrocyte parameters in detecting functional iron deficiency (FID). Methods. A total of 32 stable chronic haemodialysis patients in the maintenance phase of rHuEPO therapy were included. Classical parameters of iron monitoring and mature erythrocyte parameters were measured after a 4-week iron-free period. Patients were classified as responders (R) or non-responders (NR) to an iron load of 100 mg iron sucrose at each dialysis session for 4 weeks, according to whether their Hb increased by >1 g/dl at the end of iron loading. Results. Twelve patients were identified as responders. Receiver operating characteristic (ROC) curve analysis demonstrated %HYPO and its corresponding parameter on mature erythrocyte, %HYPOm, as the best predictors of FID. The other parameters were ordered as follows: tranferrin saturation (TSAT), ferritin (FRT), mature RBC Hb content (CHm), mean corpuscular Hb concentration (MCHC), percentage of mature erythrocytes with a low CHm (%lowCHm), mean content in Hb (MCH) and reticulocyte Hb content CHr. Comparing the parameters at different cut-offs, the best sensitivity, specificity and efficiency were demonstrated for HYPOm>6%. Conclusion. The best efficiency to predict FID was found for %HYPOm>6%. The predictive value of %HYPO was quite similar. The clinical impact of %HYPOm in iron monitoring should also be tested in the induction phase of rHuEPO treatment because of its independence from erythropoietic activity. [less ▲]

Detailed reference viewed: 53 (6 ULg)
Full Text
See detailHaematopoietic stem cell transplantation for children in Belgium
Dresse, Marie-Françoise ULg; Beguin, Yves ULg

in Tijdschrift van de Belgische Kinderarts = Journal du Pédiatre Belge (2007), 1

Detailed reference viewed: 25 (5 ULg)
Full Text
See detailLimited usefulness of CA125 measurement in the management of Hodgkin's and non-Hodgkin's lymphoma.
Bonnet, Christophe ULg; Beguin, Yves ULg; Fassotte, Marie-France ULg et al

in European Journal of Haematology (2007), 78(5), 399-404

BACKGROUND: Several papers have reported an association of high CA125 serum levels with advanced non-Hodgkin's lymphoma (NHL) as well as a relationship between high CA125 values and poor outcome. PATIENTS ... [more ▼]

BACKGROUND: Several papers have reported an association of high CA125 serum levels with advanced non-Hodgkin's lymphoma (NHL) as well as a relationship between high CA125 values and poor outcome. PATIENTS AND METHODS: Ninety-nine patients with NHL or Hodgkin's disease (HD) underwent serum CA125 assessment at diagnosis. Gender, age, presence of B symptoms, performance status (PS), histology, sites of tumor involvement, presence of effusion, clinical stage, age-adjusted International Prognostic Index, C-reactive protein (CRP), Hb, lactate deshydrogenase (LDH) and beta2-microglobulin were evaluated for their association with serum CA125 levels. The impact of CA125 levels and other features on overall (OS) and progression-free (PFS) survival was also assessed. RESULTS: CA125 serum levels were elevated in 34% of the patients, including 19% of patients with aggressive NHL, 45% of patients with indolent NHL, and 29% of patients with HD. Univariate analyses showed that CA125 levels correlated with poor PS, the presence of B symptoms, advanced clinical stage, abdominal, bone marrow or mediastinal involvement, presence of effusions, high aaIPI, low Hb levels and high CRP, LDH or beta2-microglobulin levels. In multivariate analysis, bone marrow involvement, the presence of effusions, and high aaIPI were all associated with high CA125 serum levels. In univariate analyses, OS and PFS were affected by age (PFS only), poor PS, B symptoms, advanced clinical stage, bone marrow or abdominal involvement (PFS only), high aaIPI, low Hb, high CRP or beta2-microglobulin levels. OS and PFS were not different in patients with normal or elevated CA125 levels. Multivariate analyses showed significantly inferior OS and PFS in patients with high beta2-microglobulin but no influence of CA125. CONCLUSION: While CA125 serum level correlates significantly with a number of features associated with more aggressive disease, it does not enhance the performance of standard prognostic markers in the management of patients with NHL or HD. [less ▲]

Detailed reference viewed: 62 (3 ULg)